IMAGEMEND
IMAging GEnetics for MENtal Disorders
| Coordinatore | ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Organization address
address: Square J 5 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.imagemend.eu/ |
| Totale costo | 8˙134˙274 € |
| EC contributo | 6˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Organization address
address: Square J 5 contact info |
DE (MANNHEIM) | coordinator | 705˙840.00 |
| 2 |
BRAIN INNOVATION BV
Organization address
address: OXFORDLAAN 55 contact info |
NL (MAASTRICHT) | participant | 780˙000.00 |
| 3 |
LIFE AND BRAIN GMBH
Organization address
address: SIGMUND FREUD STR 25 contact info |
DE (BONN) | participant | 720˙000.00 |
| 4 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 480˙000.00 |
| 5 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 420˙000.00 |
| 6 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 420˙000.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
Organization address
address: Piazza Umberto I 1 contact info |
IT (BARI) | participant | 420˙000.00 |
| 8 |
UNIVERSITAET BASEL
Organization address
address: Petersplatz 1 contact info |
CH (BASEL) | participant | 420˙000.00 |
| 9 |
UNIVERSITETET I OSLO
Organization address
address: Problemveien 5-7 contact info |
NO (OSLO) | participant | 420˙000.00 |
| 10 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 416˙626.00 |
| 11 |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Organization address
address: ONE GUSTAVE L LEVY PLACE BOX 1075 contact info |
US (NEW YORK) | participant | 393˙374.00 |
| 12 | Concentris Research Management GmbH | DE | participant | 300˙000.00 |
| 13 |
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
Organization address
address: REGINA PACIS WEG 3 contact info |
DE (BONN) | participant | 104˙160.00 |
| 14 |
QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
Organization address
address: "Herston Road, 300" contact info |
AU (HERSTON) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Mental disorders are leading causes of disability, absence from work and premature retirement in Europe. While magnetic resonance imaging (MRI) facilities are broadly available and a vast research literature exists, few neuroimaging applications have reached clinical practice in psychiatry. A major problem is that mental illnesses are currently diagnosed as discrete entities defined clinically. Instead, recent results show that mental disorders are best understood as quantitative alterations in neural systems relevant across traditional diagnostic boundaries that reflect individual, genetic and environmental risk factors. In the IMAGEMEND consortium, we aim to discover these systems to identify the patient characteristics most relevant for treatment, derive biomarkers and decision rules from this systems-level dimensional account, and systematically validate biomarker panels in patient, high-risk and epidemiological samples to produce automated imaging-based diagnostic and predictive tests tailored for wide distribution throughout Europe in standard clinical settings. Focusing on schizophrenia, bipolar disorder and attention deficit-hyperactivity disorder, we have assembled Europe’s largest dataset combining neuroimaging, genetic, environmental, cognitive and clinical information on approximately 13000 participants, and have recruited international replication datasets of more than 30000 people. This unique resource will be processed using a new generation of multivariate statistical analysis to optimize existing imaging technology for the benefit of patients. We will also develop new imaging technology to enable the direct imaging-based therapeutic modification of neural circuits through rapid real-time MRI. Our deliverables will promote personalized treatment through more accurate patient stratification, allow diagnoses at the pre-symptomatic stage for early intervention and prevention, and improve prediction of treatment response and disease progression.'